Turing Biosystems develops a software platform that integrates clinical and biological data to analyze patient responses to therapy and design better treatments in immunotherapy and cell & gene therapy. The platform uses interpretable AI and automated reasoning to integrate multimodal data and focus on clinical outcomes optimization.

Turing Biosystems

Turing Biosystems tackles high failure rates and adverse immune responses to immunotherapy and cell & gene therapy. Our software platform is based on a new kind of interpretable AI that works through automated reasoning. Built on specialized chips, it can integrate any and all modes of clinical/biological data,  analyse patient responses to therapies, and design better healthcare interventions. We're here to help both clinicians and biopharma get the right treatments to the right patients at the right time.

Creator Fund

We loved getting to meet and talk to clinicians at THE BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER's annual summer retreat at Dulwich College earlier this week! From translational medicine to bioinformatics, bacteriophages to T-cells in MASLD and nucleo(s)tides in hep B, it was a super-informative three days. Here's our co-founder Rémy Boutonnet talking about unmet needs in dealing with clinical data, and how we offer a patient-centric solution that moves beyond diagnostics to optimise therapies. #basl #liverdisease #automatedreasoning #ai #healthcare #clinicaldata

Because Turing Biosystems is all about making the best software for life sciences, we like to look at what brilliant minds are doing in other industries!

Very interesting talk at C++ London hosted in the beautiful offices of Maven Securities on fast and deterministic maths for MRI analysis by Tobias Wood from Imperial College London.

We were honoured to present Turing Biosystems and our progress yesterday to international investors & stakeholders at the London Stock Exchange for the Health Tech Showcase organised by the Department for Business and Trade 🇬🇧

🧬Alongside 9 other brilliant TechBio companies Sixfold Bioscience, Imperagen, CoSyne Therapeutics, CardiaTec Biosciences, Oxford Drug Design, Valink Therapeutics, PharmEnable Therapeutics, BIOS Health Ltd, Constructive Bio 

Special thanks to Bob Damms, Paul Morris, and Toby Garner from DBT for the invite & the organisation. 
🤘Amazing to see the exciting present and future of TechBio in UK and let's be bullish on London to see the next Punk TechBio company by Steve Bates OBE FMedSci. 
📈 Also great to see the initiatives coming out of the LSE to support growth of Health-Tech startups on the public market by Tim Davis.

Trending...

What is it?

In healthcare, AI is transforming everything from drug development, surgical procedures to patient care. Statista reports that AI in healthcare market was worth around 11 billion U.S. dollars worldwide in 2021 and is forecasted to be worth almost 188 billion U.S. dollars by 2030. Advancements in machine learning algorithms, data accessibility, hardware affordability, and 5G connectivity are driving the widespread adoption of AI in healthcare.

The Benefits :

1. Efficiency in administrative workflow
2. Optimized surgery procedures
3. Better health monitoring and preventive care
4. Data analysis and improved diagnosis
5. Reduced cost of care

The Companies :

Présage - Based on 4 years of clinical research, Présage is developing the 1st medical device for elderly living at home that predicts the risk of emergency hospitalization in 7-14 days.

MILVUE - Milvue has developed the first Artificial Intelligence software for radiological diagnostic assistance developed by Machine Learning engineers and expert radiologists.

Turing Biosystems - With focus on the problems of severe toxicities and elevated failure rates in immunotherapy, cell, and gene therapy, Turing Biosystems develops software that analyzes clinical and biological data to design treatments for patients.

* Search results based in USA.

Answering Vox's question: "Why are so many young people getting cancer?" Younger demographics than ever before are increasingly being diagnosed with aggressive cancers. Here's how we help identify totally new risk factors, improve diagnosis rates, and save lives. #automatedreasoning #cancertreatment #diversepatients #realworldevidence #ai #healthcare

Turing Biosystems teams presenting our collaborative work with Centre Léon Bérard and CRCL Centre de Recherche en Cancérologie de Lyon  
Where we used data from a clinical trial cohort to discover completely new insights on the biology of patients and novel drugs & therapeutic interventions to treat specific patient groups by using our interpretable reasoning AI and simulation engine.

We are at the AACR Annual Conference in San Diego with the Turing Biosystems team.

Come meet and see our poster presentation (913/28) , where we will showcase our work with collaborators from Centre Léon Bérard also relevant to our collaboration with Sanofi

Come see how we use our interpretable reasoning AI & graph engine platform to simulate the cell-cell biochemical and cellular interactions in the tumor microenvironment (TME) of oral cancers in a clinical cohort.

We will be presenting new discoveries for patient groups selection. As well as novel therapeutic discoveries with potential drugs & targets for specific patient groups identified by our reasoning-based simulations.

An example of our simulation of a patient oral tumour biopsy to identify therapeutic interventions and targets for individuals and patient groups.

🏉 Last Saturday, The Business France Rugby Club took place in Lyon the same day where our main focus was #England !

On the occasion of the 6 Nations Championship, Business France and ADERLY / Invest in Lyon, organized a special discussion moment between regional players, French businesses and foreign investors at the Business France Rugby Club. 

Thanks to the fruitful participation of fellow English companies and investors, , the testimonials of Bertrand Foucher from Aderly, Laurent Saint-Martin from Business France, Sophie Sidos from CCEF, Rachel Maury from FIBA, Adam Amara from Turing Biosystems and Serge Betsen from Serge Betsen Academy, this networking session ahead of the opening game has brought wonderful ideas and exchanges!
 
🤝 A very sincere and warm thank you to all attendees for their presence and valuable participation!
 
Laurent Saint-Martin I Marie-Cécile Tardieu I Geraldine Filippi I Business France (Invest in France) I Pascal Cagni I Mélisande R. I Jacqueline Tellier I Florence Lilti I Jérôme Julliand I Marianne PELISSIER I Julien Landfried I Frederic Miribel I Olivier Delbecq I Loïc Tchuenkam, PMP I Business France I ADERLY / Invest in Lyon I CCEF - Compagnie des Conseils et Experts Financiers I CCI de région Auvergne-Rhône-Alpes I Serge Betsen I Serge Betsen Academy I Direction générale du Trésor (French Treasury) I Franck Riester I Direction de la diplomatie économique

We're #hiring a new PhD Software Engineer C++ in France. Apply today or share this post with your network.

Excited to announce that we are winners of the EIT AI Challenge and will be working with teams at the World Health Organization on applying our interpretable AI to help them identify determinants of cancer from their multimodal data.

BIO:TURING

Turing Biosystems

Financials Not Available